273 related articles for article (PubMed ID: 22951720)
1. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
2. Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent.
Ugurel S; Paschen A; Becker JC
J Invest Dermatol; 2013 Feb; 133(2):289-92. PubMed ID: 23318786
[TBL] [Abstract][Full Text] [Related]
3. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
4. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.
Werthmöller N; Frey B; Wunderlich R; Fietkau R; Gaipl US
Cell Death Dis; 2015 May; 6(5):e1761. PubMed ID: 25973681
[TBL] [Abstract][Full Text] [Related]
5. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
6. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.
Ramacher M; Umansky V; Efferth T
Anticancer Drugs; 2009 Nov; 20(10):910-7. PubMed ID: 19745721
[TBL] [Abstract][Full Text] [Related]
7. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
[TBL] [Abstract][Full Text] [Related]
8. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
Khallouf H; Märten A; Serba S; Teichgräber V; Büchler MW; Jäger D; Schmidt J
J Immunother; 2012 Apr; 35(3):245-53. PubMed ID: 22421942
[TBL] [Abstract][Full Text] [Related]
9. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
10. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses.
Soderquest K; Walzer T; Zafirova B; Klavinskis LS; Polić B; Vivier E; Lord GM; Martín-Fontecha A
J Immunol; 2011 Mar; 186(6):3304-8. PubMed ID: 21307295
[TBL] [Abstract][Full Text] [Related]
12. Comment on "Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses".
Manjili MH; Toor A
J Immunol; 2011 Jun; 186(11):6071; author reply 6071-2. PubMed ID: 21597038
[No Abstract] [Full Text] [Related]
13. NK cells suppress CD8
Chen T; Zhang T; Liu C; Wang C; Ding S; Shao Z; Fu R
Cell Immunol; 2019 Jan; 335():6-14. PubMed ID: 30471872
[TBL] [Abstract][Full Text] [Related]
14. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.
Soriani A; Iannitto ML; Ricci B; Fionda C; Malgarini G; Morrone S; Peruzzi G; Ricciardi MR; Petrucci MT; Cippitelli M; Santoni A
J Immunol; 2014 Jul; 193(2):950-60. PubMed ID: 24913980
[TBL] [Abstract][Full Text] [Related]
15. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice.
Gao K; Li X; Zhang L; Bai L; Dong W; Gao K; Shi G; Xia X; Wu L; Zhang L
Cancer Lett; 2013 Jul; 335(2):463-71. PubMed ID: 23499895
[TBL] [Abstract][Full Text] [Related]
16. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice.
Xia Y; Chen B; Shao X; Xiao W; Qian L; Ding Y; Ji M; Gong W
J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637
[TBL] [Abstract][Full Text] [Related]
17. Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells.
Tu MM; Mahmoud AB; Wight A; Mottashed A; Bélanger S; Rahim MM; Abou-Samra E; Makrigiannis AP
Cancer Res; 2014 Jul; 74(14):3684-94. PubMed ID: 24802191
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
19. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
[TBL] [Abstract][Full Text] [Related]
20. NKG2D defines tumor-reacting effector CD8
Mojic M; Shitaoka K; Ohshima C; Ucche S; Lyu F; Hamana H; Tahara H; Kishi H; Hayakawa Y
Cancer Sci; 2021 Sep; 112(9):3484-3490. PubMed ID: 34187084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
